chlorotrianisene chlorotrianisene chlorotrianisene (cta), also known as tri-p-anisylchloroethylene (tace) and sold under the brand name tace among others, is a nonsteroidal estrogen related to diethylstilbestrol (des) which was previously used in the treatment of menopausal symptoms and estrogen deficiency in women and prostate cancer in men, among other indications, but has since been discontinued and is now no longer available. it is taken by mouth. chlorotrianiseneclinical datatrade namestace, estregur, anisene, clorotrisin, merbentyl, triagen, othersother namescta; trianisylchloroethylene; tri-p-anisylchloroethylene; tace; tris(p-methoxyphenyl)-chloroethylene; nsc-10108ahfs/drugs.commultum consumer informationroutes ofadministrationby mouthdrug classnonsteroidal estrogenatc codeg03ca06 (who) pharmacokinetic datametabolismmono-o-demethylation (liver cyp450)metabolitesdesmethylchlorotrianiseneidentifiers iupac name 1,1',1''-(2-chloroethene-1,1,2-triyl)tris(4-methoxybenzene); 11-chloro-4,13-dimethoxy-12-(p-methoxyphenyl)stilbene cas number569-57-3 ypubchem cid11289iuphar/bps7146drugbankdb00269 ychemspider10815 yunii6v5034l121keggd00269 ychebichebi:3641 ychemblchembl1200761 ycomptox dashboard (epa)dtxsid1021299 echa infocard100.008.472 chemical and physical dataformulac23h21clo3molar mass380.87 g·mol−13d model (jsmol)interactive image smiles coc1ccc(c(cl)=c(c2ccc(oc)cc2)c2ccc(oc)cc2)cc1 inchi inchi=1s/c23h21clo3/c1-25-19-10-4-16(5-11-19)22(17-6-12-20(26-2)13-7-17)23(24)18-8-14-21(27-3)15-9-18/h4-15h,1-3h3 ykey:bfpsdsiwyfkgbc-uhfffaoysa-n y (verify) cta is an estrogen, or an agonist of the estrogen receptors, the biological target of estrogens like estradiol. it is a high-efficacy partial estrogen and shows some properties of a selective estrogen receptor modulator, with predominantly estrogenic activity but also some antiestrogenic activity. cta itself is inactive and is a prodrug in the body. cta was introduced for medical use in 1952. it has been marketed in the united states and europe. however, it has since been discontinued and is no longer available in any country. medical uses cta has been used in the treatment of menopausal symptoms and estrogen deficiency in women and prostate cancer in men, among other indications. it has been used to suppress lactation in women. cta has been used in the treatment of acne as well. estrogen dosages for prostate cancer route/formestrogendosage oralestradiol1–2 mg 3x/day conjugated estrogens1.25–2.5 mg 3x/day ethinylestradiol0.15–3 mg/day ethinylestradiol sulfonate1–2 mg 1x/week diethylstilbestrol1–3 mg/day dienestrol5 mg/day hexestrol5 mg/day fosfestrol100–480 mg 1–3x/day chlorotrianisene12–48 mg/day quadrosilan900 mg/day estramustine phosphate140–1400 mg/day transdermal patchestradiol2–6x 100 μg/dayscrotal: 1x 100 μg/day im or sc injectionestradiol benzoate1.66 mg 3x/week estradiol dipropionate5 mg 1x/week estradiol valerate10–40 mg 1x/1–2 weeks estradiol undecylate100 mg 1x/4 weeks polyestradiol phosphatealone: 160–320 mg 1x/4 weekswith oral ee: 40–80 mg 1x/4 weeks estrone2–4 mg 2–3x/week iv injectionfosfestrol300–1200 mg 1–7x/week estramustine phosphate240–450 mg/day note: dosages are not necessarily equivalent. sources: see template. side effects